1-11 of 11
Doug Yee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B077: Subtype-specific signaling dynamics during treatment in non-responding breast cancer patients in the neoadjuvant I-SPY2 TRIAL: are there clues on how to overcome resistance?

Denise M. Wolf, Christina Yau, Mark Jesus M. Magbanua, Rosalyn Sayaman, Julia Wulfkhule, Rosa I. Gallagher, Lamorna Brown-Swigart, Michael J. Campbell, Amrita Basu, Gillian L. Hirst, Jane Perlmutter, Angela DeMichele, Doug Yee, Lajos Pusztai, Paula R. Pohlmann, Amy S. Clark, Hope S. Rugo, Emanuel F. Petricoin, Laura J. Esserman, Laura van ‘t Veer
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): B077.
https://doi.org/10.1158/1538-7445.ADVBC23-B077
Published: 01 February 2024
View article titled, Abstract B077: Subtype-specific signaling dynamics during treatment in non-responding breast cancer patients in the neoadjuvant I-SPY2 TRIAL: are there clues on how to overcome resistance?
Journal Articles

Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies

Hatem Soliman, Denise Wolf, Jo Chien, Christina Yau, Michael Campbell, Mark Magbanua, Ruixiao Lu, Nicholas O'Grady, Lamorna Brown-Swigart, Gillian Hirst, Beverly Parker, Laura Sit, Smita Asare, Doug Yee, Angie DeMichele, Rita Nanda, Lajos Pusztai, Don Berry, Laura Esserman, Laura Van't Veer
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD10-07.
https://doi.org/10.1158/1538-7445.SABCS21-PD10-07
Published: 15 February 2022
View article titled, Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies
Journal Articles

Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL

Denise M Wolf, Christina Yau, Michael Campbell, Hatem Soliman, Mark Magbanua, Ruixiao Lu, Nicholas O'Grady, Lamorna Brown-Swigart, Gillian Hirst, Laura Sit, Yvonne M Florence, I-SPY 2 TRIAL Investigators, Smita Asare, Doug Yee, Angie DeMichele, Don Berry, Laura Esserman, Jo Chien, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-12.
https://doi.org/10.1158/1538-7445.SABCS21-P5-13-12
Published: 15 February 2022
View article titled, Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract PS11-04: Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatment arms and molecular subtypes

Katharine Yu, Amrita Basu, Christina Yau, Denise Wolf, Gillian Hirst, Laura Sit, Nicholas O’Grady, Thelma Brown, I-SPY 2 TRIAL Investigators, Angela DeMichele, Don Berry, Nola Hylton, Doug Yee, Laura Esserman, Laura van 't Veer, Marina Sirota
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS11-04.
https://doi.org/10.1158/1538-7445.SABCS20-PS11-04
Published: 15 February 2021
View article titled, Abstract PS11-04: Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatment arms and molecular subtypes
Journal Articles

Abstract P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL

Denise M Wolf, Christina Yau, Ashish Sanil, Anneleen Daemen, Laura Heiser, Joe Gray, Lamorna Brown-Swigart, Susan Flynn, Gillian Hirst, I-SPY 2 TRIAL Investigators, Meredith Buxton, Angela DeMichele, Nola Hylton, Fraser Symmans, Doug Yee, Melissa Paoloni, Laura Esserman, Don Berry, Hope Rugo, Olufunmilayo Olopade, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-05.
https://doi.org/10.1158/1538-7445.SABCS14-P3-06-05
Published: 01 May 2015
View article titled, Abstract P3-06-05: Evaluation of an <em>in vitro</em> derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Journal Articles

Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

Christina Yau, Denise M Wolf, Ashish Sanil, Jo Chien, Anne Wallace, Judy Boughey, Doug Yee, Debu Tripathy, Angela DeMichele, Rita Nanda, Steven Chiu, Claudine Isaacs, Kathy Albain, Hank Kaplan, Stacey Moulder, Rebecca Viscusi, Donald Northfelt, Kirsten Edmiston, Anthony Elias, Toncred Styblo, Barbara Haley, Lamorna Brown-Swigart, Susan Flynn, Gillian L Hirst, Meredith Buxton, Nola Hylton, Melissa Paoloni, W Fraser Symmans, Laura Esserman, Don Berry, Minetta C Liu, John W Park, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-29.
https://doi.org/10.1158/1538-7445.SABCS14-P3-06-29
Published: 01 May 2015
View article titled, Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Journal Articles

Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial

Christina Yau, Denise Wolf, Ashish Sanil, Laura van 't Veer, Emanuel F Petricoin, Meredith Buxton, Joe Gray, Angela DeMichele, Mike Hogarth, Nola Hylton, Jane Perlmutter, Melissa Paoloni, Fraser Symmans, Doug Yee, Don Berry, Laura Esserman
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-37.
https://doi.org/10.1158/1538-7445.SABCS14-P3-06-37
Published: 01 May 2015
View article titled, Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial
Journal Articles

Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

Denise M Wolf, Christina Yau, Ashish Sanil, Jo Chien, Anne Wallace, Angela DeMichele, Hank Kaplan, Doug Yee, Claudine Isaacs, Kathy Albain, Rebecca Viscuzi, Judy Boughey, Stacey Moulder, Steven Chui, Qamar Khan, Toncred Styblo, Kirsten Edmiston, Donald Northfelt, Anthony Elias, Barbara Haley, Debu Tripathy, Lamorna Brown-Swigart, Susan Flynn, Gillian Hirst, Meredith Buxton, Nola Hylton, Melissa Paoloni, Fraser Symmans, Laura Esserman, Don Berry, Hope Rugo, Olufunmilayo I. Olopade, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-25.
https://doi.org/10.1158/1538-7445.SABCS14-P3-06-25
Published: 01 May 2015
View article titled, Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Journal Articles

Endpoint determination for gemcitabine treatment in the in vitro cell culture bioreactor system

Mark N. Kirstein, Richard C. Brundage, Megan M. Moore, Lisa A. Hillman, Paul H. Marker, Robert A. Kratzke, Doug Yee
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 733.
Published: 15 April 2006
View article titled, Endpoint determination for gemcitabine treatment in the in vitro cell culture bioreactor system
Journal Articles

Development of an in vitro cell culture hollow fiber system to evaluate anti-neoplastic drug regimens

Mark N. Kirstein, Richard C. Brundage, William F. Elmquist, Rory P. Remmel, Dan E. Guire, Doug Yee
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 981.
Published: 01 May 2005
View article titled, Development of an <em>in vitro</em> cell culture hollow fiber system to evaluate anti-neoplastic drug regimens
Journal Articles

Morphine Stimulates Angiogenesis by Activating Proangiogenic and Survival-promoting Signaling and Promotes Breast Tumor Growth

Kalpna Gupta, Smita Kshirsagar, Liming Chang, Robert Schwartz, Ping-Y. Law, Doug Yee, Robert P. Hebbel
Journal: Cancer Research
Cancer Res (2002) 62 (15): 4491–4498.
Published: 01 August 2002
View article titled, Morphine Stimulates Angiogenesis by Activating Proangiogenic and Survival-promoting Signaling and Promotes Breast Tumor Growth
Open the PDF for Morphine Stimulates Angiogenesis by Activating Proangiogenic and Survival-promoting Signaling and Promotes Breast Tumor Growth in another window